All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

People with severe mental illness (SMI) (schizophrenia and other illnesses characterised by psychosis) have a lower life expectancy compared with the general population by around 15 to 20 years \[[@pone.0168549.ref001]\]. A higher prevalence of comorbid conditions (e.g. diabetes and cardiovascular disease) and poorer management of physical health contribute to this health inequality \[[@pone.0168549.ref002]\]. Around 13% of people with SMI have diabetes compared with 6% of the general population, and the difference is increasing \[[@pone.0168549.ref003]\]. As diabetes interventions are scaled up for the general population, these inequalities may increase further. This is because generic interventions are unlikely to be suitable for people with SMI due to the complex combination of psychological, social and financial barriers they face in managing their health \[[@pone.0168549.ref004]\].

Although there are more than 40 published systematic reviews of studies targeting physical health in people with SMI, these have focused mainly on anthropological outcomes \[[@pone.0168549.ref005]--[@pone.0168549.ref008]\], with few investigating diabetes prevention and treatment \[[@pone.0168549.ref009], [@pone.0168549.ref010]\]. It is well-established that modest improvements in glycated haemoglobin (HbA~1c~) and blood glucose levels can avoid onset of diabetes and have a significant impact on preventing diabetic complications in the general population \[[@pone.0168549.ref011]\]. A few reviews have investigated the effect of pharmacological \[[@pone.0168549.ref006], [@pone.0168549.ref012]\] and behavioural \[[@pone.0168549.ref007], [@pone.0168549.ref008], [@pone.0168549.ref013]\] interventions on these glycaemic measurements in people with SMI. An older review investigated both pharmacological and behavioural interventions \[[@pone.0168549.ref014]\]. However in all of these, glycaemic effects were examined as a secondary outcome only. This makes it difficult to determine which interventions are effective for improving glycaemic control in people with SMI. The aim of this systematic review and meta-analysis is to identify pharmacological and behavioural interventions for improving diabetes outcomes that have been tested in the adult SMI population, and to determine their effectiveness in lowering HbA~1c~ and fasting blood glucose \[[@pone.0168549.ref015]\].

Methods {#sec002}
=======

Eligibility criteria {#sec003}
--------------------

We included randomised controlled trials (RCTs) of interventions to improve diabetes outcomes for adults (aged 18 years and over) with SMI. We defined SMI as schizophrenia, bipolar disorder, psychosis or other non-organic psychotic disorders, including schizoaffective disorder and severe depression. To be included, studies had to measure at least one of the following outcomes: i) in people without diabetes at baseline: incidence of diabetes, HbA~1c~ or fasting glucose; and ii) in people with diabetes at baseline: HbA~1c~, fasting glucose, weight, body mass index (BMI), or diabetic complications.

We restricted studies to those published in peer reviewed journals and the English language.

The protocol for the review has been published on the International Prospective Register of Systematic Reviews (PROSPERO), registration number CRD42015015558 \[[@pone.0168549.ref015]\]. We carried out the review in accordance with the PRISMA guidelines (see [S1 PRISMA Checklist](#pone.0168549.s001){ref-type="supplementary-material"}).

Search strategy {#sec004}
---------------

The search strategy comprised three concepts: 'diabetes', 'SMI', and 'RCTs or systematic reviews'. An example of the strategy is provided in the supporting information (see [S1 Appendix](#pone.0168549.s002){ref-type="supplementary-material"}).

Literature searches were performed in CINAHL (EBSCO); Embase Classic+Embase (Ovid); PsycINFO (Ovid); Ovid Medline; PubMed; Cochrane Database of Systematic Reviews (Wiley) and Central Register of Controlled Trials; Database of Abstracts of Reviews of Effect (Wiley); and Conference Proceedings Citation Index (Thomson Reuters). We also searched three trial registries (ClinicalTrials.gov, International Clinical Trials Registry Platform (WHO), ISRCTN registry). Searches were performed on 12/12/2014, and updated on 30/10/2015 (except for trial registries).

Study selection {#sec005}
---------------

Search results were managed in EndNote version 7 software. Citations and abstracts were screened to exclude studies that did not meet the selection criteria. References of relevant reviews identified during the screening process were also searched. Relevant full-text articles were retrieved and assessed for eligibility; missing data to help assess eligibility were sought from corresponding authors.

Data extraction and synthesis {#sec006}
-----------------------------

Study characteristics and data for meta-analysis were extracted into a tailored and piloted data collection form \[[@pone.0168549.ref015]\]. Multiple reports from the same study were linked and missing data were requested from study authors. The Cochrane Collaboration tool was used to assess risk of bias \[[@pone.0168549.ref016]\]. All stages of study selection and data extraction were conducted independently by two reviewers, with discrepancies resolved through discussion and where consensus could not be reached, arbitration by a third reviewer.

Due to the heterogeneity of diabetes interventions, we categorised interventions as pharmacological, non-pharmacological or mixed (interventions combining medication with a non-pharmacological approach) \[[@pone.0168549.ref015]\]. Pharmacological interventions were further sub-grouped into categories: i) diabetes medications (including metformin, sulphonylureas, insulin and thiazolidinediones); ii) weight loss treatments (including antiparkinsonian, anticonvulsant and antidepressant medications thought to promote weight loss, as well as anti-obesity drugs and appetite suppressants); iii) combinations of weight loss and diabetes medications; iv) switching antipsychotic medication; and v) an 'other' category.

Non-pharmacological interventions were categorised as behavioural (targeting a change in an individual's behaviour) or organisational (targeting a change in the environment or organisation of care).

We planned to explore effectiveness of interventions in prevention of diabetes. However, many studies did not distinguish between people with and without diabetes at baseline. Of the studies that excluded people with diabetes at baseline, none measured incidence of diabetes or reported data that would enable us to estimate this. We therefore pooled the results across all studies for glycaemic control, using outcome data for HbA~1c~ and fasting glucose.

We analysed pharmacological and non-pharmacological interventions separately, and because we expected significant heterogeneity between studies, we used random-effects meta-analysis and assessed for heterogeneity using the I-squared statistic. To allow combining of post-intervention and change scores for outcomes, and since outcomes were reported consistently, we calculated the unstandardised difference in means (MD) \[[@pone.0168549.ref016]\].

To assess effects across key intervention characteristics, we conducted subgroup analyses for pharmacological interventions by type of drug category; and for behavioural interventions by duration (short (≤6 months) or long (\>6 months)), and whether or not interventions included repeated physical activity. We also conducted univariate random effects meta-regression using intervention duration as a continuous variable (number of weeks). Both duration and physical activity have been identified as key components of effective diabetes interventions in the general population \[[@pone.0168549.ref017]\].

To explore potential differential effects in people with and without diabetes, we conducted separate subgroup analyses, for i) studies excluding participants with diabetes, and ii) those that only included people with diabetes and SMI or did not specify diabetes status. We also conducted univariate random effects meta-regression using mean HbA~1c~ or fasting glucose at baseline to explore whether or not this explained some of the heterogeneity among studies \[[@pone.0168549.ref018]\].

To investigate possible baseline imbalance observed during data extraction, we repeated the main meta-analyses using mean difference at baseline \[[@pone.0168549.ref019]\]. We explored the impact of study quality and heterogeneity by undertaking sensitivity analyses, using 'leave-one-out' analyses to test if single studies had a disproportionate effect on the results. We used the trim-and-fill method and inspection of funnel plots to investigate publication and small study bias \[[@pone.0168549.ref020]\]. The trim-and-fill analysis adjusts for any funnel plot asymmetry and provides an effect size estimate that takes account of observed publication bias.

Comprehensive Meta-Analysis (CMA) version 2 software was used for all statistical analyses.

Results {#sec007}
=======

A total of 3,721 citations were identified by database searches, and a further 27 articles from the reference lists of systematic reviews. After removing duplicates, 2,278 records were screened for relevance by title and abstract, and 197 full text articles retrieved. Of these, 104 did not meet the selection criteria and were excluded. The remaining 93 articles described 73 studies. Nineteen of these were ongoing studies (see [S1 Table](#pone.0168549.s003){ref-type="supplementary-material"}).

A total of 54 studies were included in the systematic review \[[@pone.0168549.ref021]--[@pone.0168549.ref074]\]. Six of these studies did not provide usable data for the meta-analysis \[[@pone.0168549.ref026], [@pone.0168549.ref032], [@pone.0168549.ref042], [@pone.0168549.ref044], [@pone.0168549.ref046], [@pone.0168549.ref051]\]. [Fig 1](#pone.0168549.g001){ref-type="fig"} presents a study flow diagram.

![Study flow diagram.](pone.0168549.g001){#pone.0168549.g001}

Study characteristics are summarised in [Table 1](#pone.0168549.t001){ref-type="table"}.

10.1371/journal.pone.0168549.t001

###### Characteristics of Included Studies.

![](pone.0168549.t001){#pone.0168549.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID and country                                                                                                                                 Study aim                                                                                                                                          Setting (number randomised)                                                                                                                      SMI diagnoses                                                                                                                            Diabetes diagnoses                                                                         Other relevant inclusion criteria                                                                     Intervention duration and frequency / dosage                                                                                                             Control                                                                                                       Follow-up time points[^a^](#t001fn003){ref-type="table-fn"}   Primary outcome[^b^](#t001fn004){ref-type="table-fn"}                                 Diabetes outcomes
  ---------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------
  **BEHAVIOURAL INTERVENTIONS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Attux 2013 \[[@pone.0168549.ref021]\], Brazil                                                                                                        Test efficacy of a lifestyle wellness intervention for weight gain management in schizophrenia                                                     Patients attending four outpatient units (n = 160)                                                                                               • Schizophrenia diagnosis\                                                                                                               Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 12 weeks\                                                                                                                                    Standard care                                                                                                 **3 months**\                                                 **Change in body weight** [^**c**^](#t001fn005){ref-type="table-fn"}                  Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Using any APM for past 3 months\                                                                                                                                                                                                  • Excluded patients using weight loss medication\                                                     • Manualised: YES\                                                                                                                                                                                                                                                     • 6 months                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Clinically stable                                                                                                                                                                                                                 • Motivation to lose weight                                                                           • Group: 12 weekly 1-hour sessions\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: trained MHP                                                                                                                                                                                                                                                                                                                                                                                                     

  Cordes 2014 \[[@pone.0168549.ref022]\], Germany                                                                                                      Investigate effects of weight loss programme on body weight and metabolic parameters in schizophrenia patients on OLZ                              In-patients of one psychiatric facility (n = 74)                                                                                                 • Schizophrenia diagnosis\                                                                                                               Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 24 weeks\                                                                                                                                    Treatment as usual                                                                                            **24 weeks**\                                                 **Change in body weight** [^**d**^](#t001fn006){ref-type="table-fn"}                  **Fasting plasma glucose** [^**d**^](#t001fn006){ref-type="table-fn"}**, OGTT** [^**d**^](#t001fn006){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • New treatment with OLZ\                                                                                                                                                                                                           • Excluded weight gain of \> 3kg in 3 months preceding\                                               • Manualised: YES\                                                                                                                                                                                                                                                     • 48 weeks                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Weight gain of \> 1.5kg in 4 weeks of taking OLZ                                                                                                                                                                                  • Excluded weight loss medication                                                                     • Group: 12 bi-weekly 90-minute sessions\                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Dietician with mental health counselling experience                                                                                                                                                                                                                                                                                                                                                             

  Daumit 2013 \[[@pone.0168549.ref023]\], US                                                                                                           Determine effectiveness of behavioural weight-loss intervention in SMI                                                                             Patients of ten community outpatient psychiatric rehabilitation programmes (n = 291)                                                             • Attending psychiatric rehabilitation programme\                                                                                                                                                                                   • Age 18 and older\                                                                                   • Duration: 18 months\                                                                                                                                   Nutrition and physical activity information at baseline, offered quarterly general health classes             • 6 months\                                                   **Change in body weight**                                                             Fasting blood glucose [^**e**^](#t001fn007){ref-type="table-fn"} (no p-value)
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • On same APM for 30 days prior to study                                                                                                                                                                                            • BMI ≥ 25\                                                                                           • Manualised: YES\                                                                                                                                                                                                                                                     • 12 months\                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight gain of \> 20lbs in 3 months prior\                                                 • Group: 3 times per week for 6 months, then monthly sessions for 12 months\                                                                                                                                                                                           • **18 months**                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medication                                                                     • Individual: Yes if required\                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: trained study staff and rehabilitation staff                                                                                                                                                                                                                                                                                                                                                                    

  Forsberg 2008 \[[@pone.0168549.ref024]\], Sweden                                                                                                     Investigate effects of a lifestyle programme on metabolic syndrome and physiological parameters in psychiatric disability                          Adults with a psychiatric disability receiving housing support or in supported housing (n = 46 [^**f**^](#t001fn008){ref-type="table-fn"}**)**   • A psychiatric diagnosis in accordance with DSM-IV                                                                                                                                                                                                                                                                                       • Duration: 12 months\                                                                                                                                   Controls offered an aesthetic study circle to learn artistic techniques, group-based weekly 2 hour sessions   • 12 months                                                   Presence of MetS\                                                                     Fasting plasma glucose, HbA~1c~
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Manualised: YES\                                                                                                                                                                                                                                                                                                                   • **, mean no. criteria for MetS**                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: 2-hour study circle for 5--12 residents and staff held twice weekly for 12 months\                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: participating staff with no training                                                                                                                                                                                                                                                                                                                                                                            

  Gillhoff 2010 \[[@pone.0168549.ref025]\], Switzerland                                                                                                Evaluate effects of lifestyle intervention on BMI and cardiovascular and metabolic parameters in bipolar disorder                                  Outpatients of a psychiatric hospital and associated psychiatrists, study advertised in local press (n = 50)                                     • Bipolar disorder diagnosis\                                                                                                            Excluded patients with diabetes                                                            • Age 18 to 70\                                                                                       • Duration: 5 monthsManualised: YES\                                                                                                                     Standard care (wait list)                                                                                     **3 months**\                                                 **BMI**[^**g**^](#t001fn009){ref-type="table-fn"}                                     HbA~1c~
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving psycho-pharmacologic treatment for 3 months                                                                                                                                                                             • Not underweight (BMI \> 20)\                                                                        • Group: Weekly sessions for 11 weeks\                                                                                                                                                                                                                                 • 11 months                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medication                                                                     • Individual: Yes if required\                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: MHP, nutrition counsellor and fitness trainer                                                                                                                                                                                                                                                                                                                                                                   

  Goldberg 2013 \[[@pone.0168549.ref026]\], US **(excluded from meta-analysis)**                                                                       Evaluate effects of weight management programme on body weight in Veterans with SMI                                                                Outpatients of Veteran Association mental health clinics (n = 109)                                                                               • DSM-IV diagnosis of schizophrenia, other psychotic spectrum disorder, bipolar disorder, major depression, or severe anxiety disorder   Excluded patients with elevated HbA~1c~ or fasting glucose levels                          • Age 18 to 75\                                                                                       • Duration: 6 months\                                                                                                                                    Offered basic information about diet and exercise each month                                                  **3 months**\                                                 Weight loss                                                                           Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • BMI ≥ 25\                                                                                           • Manualised: YES\                                                                                                                                                                                                                                                     • Plus interim monthly weigh-in                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medication in 3 months prior to study                                          • Group: Weekly sessions in months 2--4, biweekly in months 5--6\                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Individual: Weekly sessions in month 1\                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Research staff                                                                                                                                                                                                                                                                                                                                                                                                  

  Green 2015 \[[@pone.0168549.ref027]\], US                                                                                                            Assess whether lifestyle intervention reduces weight and diabetes risk in individuals with SMI                                                     Outpatients of community mental health centres and a not-for-profit integrated health plan (n = 200)                                             • Taking antipsychotic medication for ≥ 30 days prior to study                                                                                                                                                                      • Age 18 and older\                                                                                   • Duration: 6 months + 6 months maintenance\                                                                                                             Usual care and free to initiate any weight loss effort on their own                                           • 6 months\                                                   **Weight loss**                                                                       **Fasting plasma glucose**
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • BMI ≥ 27                                                                                            • Manualised: YES\                                                                                                                                                                                                                                                     • **12 months**\                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: Weekly 2-hour sessions in months 1--6, monthly in 7--12\                                                                                                                                                                                                      • 24 months                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Individual: Monthly call / email in months 7--12\                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: 2 facilitators (nutrition & counselling)                                                                                                                                                                                                                                                                                                                                                                        

  Mauri 2008 \[[@pone.0168549.ref028]\], US                                                                                                            Evaluate efficacy of psycho-educational weight loss programme for patients with OLZ induced weight gain                                            Psychiatric outpatients (n = 45 [^**h**^](#t001fn010){ref-type="table-fn"}**)**                                                                  • Receiving treatment of OLZ                                                                                                                                                                                                        • Age 18 to 65\                                                                                       • Duration: 24 weeks\                                                                                                                                    Routine care in weeks 1--12, intervention in weeks 13--24                                                     **12 weeks**\                                                 **Weight loss**                                                                       Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Increase of BMI (\>7%) during treatment with OLZ                                                    • Manualised: Not reported\                                                                                                                                                                                                                                            • 24 weeks                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Sessions: Weekly 30-minute sessions for 24 weeks (not stated if group or individual)\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Not reported                                                                                                                                                                                                                                                                                                                                                                                                    

  McKibben 2006 \[[@pone.0168549.ref029]\], US                                                                                                         Test feasibility and efficacy of lifestyle intervention for older patients with type 2 diabetes and schizophrenia                                  Residential care facilities, day programmes and community clubhouse settings (n = 64)                                                            • Diagnosis of schizophrenia or schizoaffective disorder                                                                                 Only included type 2 diabetes                                                              • Age over 40\                                                                                        • Duration: 24 weeks\                                                                                                                                    Usual care plus written information about managing diabetes                                                   **3 months**\                                                 **BMI**                                                                               Fasting plasma glucose, HbA~1c~
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded patients with congestive heart failure                                                     • Manualised: YES\                                                                                                                                                                                                                                                     • 12 months                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: Weekly 90-minute sessions for 24 weeks\                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Diabetes-trained MHP                                                                                                                                                                                                                                                                                                                                                                                            

  Poulin 2007 \[[@pone.0168549.ref030]\], Canada                                                                                                       Determine effectiveness of physical exercise programme for preventing APM-induced weight gain in patients with SMI                                 Outpatients of psychiatric departments in two hospitals (n = 130)                                                                                • DSM-IV diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder\                                                                                                                                                  • Age 18 and over\                                                                                    • Duration: 18 months\                                                                                                                                   Usual care                                                                                                    • 6 months\                                                   **Change in body weight**                                                             **Fasting plasma glucose, HbA**~**1c**~ [^**i**^](#t001fn011){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Current treatment with atypical APM                                                                                                                                                                                               • Only included sedentary or moderately active patients                                               • Manualised: NR\                                                                                                                                                                                                                                                      • 12 months\                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: One 90-minute counselling session followed by twice weekly 1-hour exercise sessions for 18 months\                                                                                                                                                            • **18 months**                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Nutritionist, MH nurse, kinesiologist                                                                                                                                                                                                                                                                                                                                                                           

  Scheewe 2013 \[[@pone.0168549.ref031]\], Netherlands                                                                                                 Examine effect of exercise vs OT on mental and physical health in schizophrenia patients                                                           In-patients and out-patients of a University Medical Centre and three regional MH institutes (n = 63)                                            • DSM-IV diagnosis of schizophrenia, schizoaffective or schizophreniform disorder\                                                                                                                                                  • No evidence of significant cardio-vascular disorder                                                 • Duration: 6 months\                                                                                                                                    • Active control: OT\                                                                                         • 6 months                                                    Mental health: Positive and negative symptoms **Physical health:CV fitness levels**   Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Stable on APM                                                                                                                                                                                                                                                                                                                           • Manualised: YES\                                                                                                                                       • Group: Twice weekly 1-hour sessions for 6 months\                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: Twice weekly 1-hour sessions for 6 months\                                                                                                      • Individual: None\                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Supervised by psychomotor therapist                                                                                                           • Leaders: OT                                                                                                                                                                                                                                                     

  Weber 2006 \[[@pone.0168549.ref032]\], US **(excluded from meta-analysis)**                                                                          Examine effectiveness of cognitive behavioural intervention for weight loss in schizophrenia patients taking APM                                   Outpatients attending a large urban public mental health clinic (n = 17)                                                                         • DSM-IV diagnosis of schizophrenia or schizoaffective disorder                                                                                                                                                                     • Age 18 to 65\                                                                                       • Duration: 16 weeks\                                                                                                                                    Treatment as usual                                                                                            • Week 4\                                                     Weight loss                                                                           Fasting glucose [^j^](#t001fn012){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • BMI ≥ 25                                                                                            • Manualised: YES\                                                                                                                                                                                                                                                     • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: Weekly 1-hour sessions for 16 weeks\                                                                                                                                                                                                                          • Week 12\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: MH nurse practitioner                                                                                                                                                                                                                                       • **Week 16**                                                                                                                                       

  Wu 2007 \[[@pone.0168549.ref033]\], Taiwan                                                                                                           Evaluate effects of dietary control and physical activity for CLZ induced weight gain in schizophrenia patients                                    Inpatients of a veterans hospital (n = 53)                                                                                                       • DSM-IV diagnosis of schizophrenia\                                                                                                                                                                                                • Age 18 to 65\                                                                                       • Duration: 6 months\                                                                                                                                    NR                                                                                                            • 3 months\                                                   **Weight loss**                                                                       Serum fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving treatment of CLZ (\>300mg daily for at least 1 year)                                                                                                                                                                    • BMI ≥ 27                                                                                            • Manualised: NR\                                                                                                                                                                                                                                                      • **6 months**                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Individual: Restricted caloric intake and physical activity of \>30 minutes 3 times/week\                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Registered dietician                                                                                                                                                                                                                                                                                                                                                                                            

  **MIXED INTERVENTIONS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Wu 2008 A \[[@pone.0168549.ref034]\] [^**k**^](#t001fn013){ref-type="table-fn"}, China                                                               Test efficacy of lifestyle intervention and / or metformin for APM induced weight gain in schizophrenia patients                                   Outpatient clinic of one regional hospital (n = 128), 4 arm trial                                                                                • First psychotic episode of schizophrenia (DSM-IV diagnosis)\                                                                           Excluded patients with diabetes                                                            • Age 18 to 45\                                                                                       • Duration: 12 weeks\                                                                                                                                    **D: Placebo**                                                                                                • Week 4\                                                     **Change in body weight**                                                             **Fasting glucose**
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Weight gain of \> 10% within first year of APM treatment\                                                                                                                                                                         • Under the care of parent or another adult caregiver                                                 • **A: Lifestyle PLUS placebo**\                                                                                                                                                                                                                                       • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Only taking CLZ, OLZ, risperidone, or sulpiride                                                                                                                                                                                                                                                                                         • Manualised: NR\                                                                                                                                                                                                                                                      • **Week 12**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Group: Lifestyle sessions at baseline, weeks 4, 8, and 12 PLUS daily 30-minute exercise in week 1\                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Leaders: Exercise physiologist and dietician\                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • **B: Metformin**\                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 250mg/day for 4 days, then 750mg (250mg x 3)/day to week 12\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • **C: Lifestyle AND metformin**                                                                                                                                                                                                                                                                                                                                                                                           

  **PHARMACOLOGICAL INTERVENTIONS**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Amrami-Weizman 2013 \[[@pone.0168549.ref035]\], Israel                                                                                               Investigate effects of reboxetine on OLZ induced weight gain and metabolic parameters in schizophrenia patients                                    Inpatients of one mental health centre (pilot n = 26, trial n = 59 [^**l**^](#t001fn011){ref-type="table-fn"})                                   • First episode of schizophrenia (DSM-IV diagnosis)\                                                                                     Excluded patients with diabetes                                                            • BMI \< 30 (i.e. excluded obese participants)                                                        • Duration: 6 weeks\                                                                                                                                     OLZ (10mg/day) PLUS Placebo                                                                                   • Week 6                                                      **Change in body weight**                                                             Serum fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Recommendation for OLZ treatment on hospitalization\                                                                                                                                                                                                                                                                                    • OLZ (10mg/day) PLUS Reboxetine\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • \< 4 weeks exposure to APM in preceding 6 months (no OLZ)                                                                                                                                                                                                                                                                               • Dose: 2mg twice daily (4mg/day)                                                                                                                                                                                                                                                                                                                                                                                          

  Baptista 2006 \[[@pone.0168549.ref036]\], Venezuela                                                                                                  Assess whether metformin prevents body weight gain and metabolic dysfunction in patients with schizophrenia switched to OLZ                        Inpatients of psychiatric rehabilitation unit (n = 40)                                                                                           • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Free of any other chronic disease                                                                                                                                                                • Duration: 14 weeks\                                                                                                                                    OLZ (10mg/day) PLUS Placebo                                                                                   • Week 7\                                                     Change in body weight                                                                 Fasting glucose, OGTT
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Stable for more than 5 years with conventional APM\                                                                                                                                                                                                                                                                                     • OLZ (10mg/day) PLUS Metformin\                                                                                                                                                                                                                                       • **Week 14**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Switching to OLZ                                                                                                                                                                                                                                                                                                                        • Dose: 850 to 1750mg/day                                                                                                                                                                                                                                                                                                                                                                                                  

  Baptista 2007 \[[@pone.0168549.ref037]\], Venezuela                                                                                                  Assess whether metformin reverses OLZ induced weight gain and metabolic dysfunction in patients with SMI                                           Out- and inpatients in three states of Venezuela (n = 80)                                                                                        • DSM-IV diagnosis of schizophrenia or bipolar disorder\                                                                                 Free of any other chronic disease                                                          • Age 18 and over\                                                                                    • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12                                                     Weight loss                                                                           HbA~1c~, fasting serum glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving treatment with OLZ (5--20mg daily for more than 4 months preceding)                                                                                                                                                     • Be willing to lose weight or prevent excessive body weight gain                                     • Metformin\                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 850mg daily increased up to 2250mg by week 4 (adjusted according to individual tolerance)                                                                                                                                                                                                                                                                                                                          

  Baptista 2008 \[[@pone.0168549.ref038]\], Venezuela                                                                                                  Assess whether metformin plus sibutramine reverses OLZ induced weight gain and metabolic dysfunction in patients with schizophrenia                Inpatients of psychiatric rehabilitation unit (n = 30)                                                                                           • DSM-IV diagnosis of schizophrenia\                                                                                                     Free of any other chronic disease                                                          • Age 18 and over\                                                                                    • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12                                                     Change in body weight                                                                 HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Stable for more than 5 years\                                                                                                                                                                                                     • Be willing to lose weight or prevent excessive body weight gain                                     • Metformin plus sibutramine\                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Switched from conventional APM to OLZ monotherapy 4 months prior to study                                                                                                                                                                                                                                                               • Dose: Week 1 to 4--850mg metformin plus 10mg sibutramine daily, week 5 to 12--850mg metformin plus 10mg sibutramine twice daily                                                                                                                                                                                                                                                                                          

  Baptista 2009 \[[@pone.0168549.ref039]\], Venezuela                                                                                                  Assess the effects of rosiglitazone on body weight and metabolic parameters in patients with schizophrenia receiving OLZ                           Inpatients of psychiatric rehabilitation unit (n = 30)                                                                                           • DSM-IV diagnosis of schizophrenia\                                                                                                     Free of any other chronic disease                                                          • Age 18 and over\                                                                                    • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 6\                                                     Change in body weight                                                                 HbA~1c~, fasting serum glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Stable for more than 5 years\                                                                                                                                                                                                     • Be willing to lose weight or prevent excessive body weight gain                                     • Rosiglitazone\                                                                                                                                                                                                                                                       • **Week 12**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Switched from conventional APM to OLZ monotherapy 8 months prior to study                                                                                                                                                                                                                                                               • Dose: 4mg daily increased up to 8mg daily from week 4                                                                                                                                                                                                                                                                                                                                                                    

  Biedermann 2013 \[[@pone.0168549.ref040]\], Austria                                                                                                  Investigate effect of sibutramine for APM induced weight gain in patients with schizophrenia                                                       Outpatients (n = 15)                                                                                                                             • Diagnosis of schizophrenia (following ICD-10)\                                                                                                                                                                                    • Age 19 to 65\                                                                                       • Duration: 24 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12\                                                    **Change in body weight**                                                             **HbA**~**1c**~, random glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving APM treatment                                                                                                                                                                                                           • BMI \> 27\                                                                                          • Sibutramine\                                                                                                                                                                                                                                                         • **Week 24**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Gained at least 7% body weight during APM treatment                                                 • Dose: 10mg daily                                                                                                                                                                                                                                                                                                                                                                                                         

  Borba 2011 \[[@pone.0168549.ref041]\], US                                                                                                            Examine the effects of ramelteon for APM induced weight gain and metabolic disturbances in patients with schizophrenia                             Outpatients of one mental health centre (n = 25)                                                                                                 • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded patients with diabetes or diabetic fasting glucose levels                         • Age 18 to 65\                                                                                       • Duration: 8 weeks\                                                                                                                                     Placebo                                                                                                       • Week 8                                                      Change in body weight                                                                 HbA~1c~, fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Clinically stable\                                                                                                                                                                                                                • BMI \> 27\                                                                                          • Ramelteon\                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving APM treatment of CLZ, OLZ, risperidone or quetiapine                                                                                                                                                                    • Evidence of insulin resistance or MetS\                                                             • Dose: 8mg daily                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded patients using weight loss medication                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Borovicka 2002 \[[@pone.0168549.ref042]\], US **(excluded from meta-analysis)**                                                                      Investigate the effects of PPA for managing CLZ induced weight gain in patients with schizophrenia                                                 Outpatients of a CLZ treatment programme (n = 16)                                                                                                • DSM-IV diagnosis of schizophrenia\                                                                                                     Excluded patients with diabetes                                                            • \> 10% increase in body weight since starting CLZ\                                                  • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 4\                                                     Change in body weight                                                                 HbA~1c~ [^**m**^](#t001fn015){ref-type="table-fn"}, random glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • On stable dose of CLZ for \> 4 months                                                                                                                                                                                             • Excluded previous weight loss medication                                                            • PPA\                                                                                                                                                                                                                                                                 • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 75mg sustained-release daily                                                                                                                                                                                                                                   • **Week 12**                                                                                                                                       

  Carrizo 2009 \[[@pone.0168549.ref043]\], Venezuela                                                                                                   Test whether extended release metformin improves the metabolic profile of patients receiving CLZ                                                   Patients of a schizophrenia outpatient centre (n = 61)                                                                                           • Receiving CLZ for \> 3 months preceding                                                                                                                                                                                           • Age 18 and over                                                                                     • Duration: 14 weeks\                                                                                                                                    Placebo                                                                                                       • Week 7\                                                     **Change in body weight**                                                             **HbA**~**1c**~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Metformin\                                                                                                                                                                                                                                                           • **Week 14**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 500mg/day for 2 weeks increased to 1000mg/day for 12 weeks                                                                                                                                                                                                                                                                                                                                                         

  Chen 2012 \[[@pone.0168549.ref044]\], US [^n^](#t001fn016){ref-type="table-fn"} **(excluded from meta-analysis)**                                    Test the effects of switching from current APM to aripiprazole or ziprasidone for patients with SMI and evidence of insulin resistance             Outpatients of three community-based clinical centres (n = 52)                                                                                   • DSM-IV diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder\                                                                                                                                                  • Age 18 to 64\                                                                                       • Duration: 52 weeks\                                                                                                                                    Ziprasidone, dose: 40 to 160mg/day titrated to target dose in 2 weeks                                         • Week 6\                                                     Change in body weight                                                                 HbA~1c~
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving APM treatment (no previous ARIP / ZIP)                                                                                                                                                                                  • Evidence of insulin resistance                                                                      • Aripiprazole\                                                                                                                                                                                                                                                        • Week 12\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 5 to 30mg/day titrated to reach target dose within 2 weeks                                                                                                                                                                                                     • Week 26\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • **Week 52**                                                                                                                                       

  Chen 2013 \[[@pone.0168549.ref045]\], Taiwan                                                                                                         Test the effectiveness of metformin for controlling metabolic abnormalities in CLZ-treated patients with schizophrenia                             In- and out-patients from psychiatric rehabilitation wards and two outpatient clinics (n = 55)                                                   • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded diabetes diagnoses or diabetic fasting plasma glucose levels                      • Age 20 to 65\                                                                                       • Duration: 24 weeks\                                                                                                                                    Placebo                                                                                                       • Week 2\                                                     **Change in body weight**                                                             Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving CLZ for \> 3 months preceding                                                                                                                                                                                           • BMI ≥ 24\                                                                                           • Metformin\                                                                                                                                                                                                                                                           • Week 4\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Fulfilled at least 1 criteria of MetS\                                                              • Dose: 500mg twice daily (1000mg/day) in week 1 increased to 500mg 3 times daily (1500mg/day) in week 2                                                                                                                                                               • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medications                                                                                                                                                                                                                                                                                                                                           • Week 16\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • **Week 24**\                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • 24 weeks after end                                                                                                                                

  Deberdt 2005 \[[@pone.0168549.ref046]\], US **(excluded from meta-analysis)**                                                                        Examine efficacy of amantadine for managing OLZ induced weight gain in patients with SMI                                                           In- and outpatients (n = 125)                                                                                                                    • DSM-IV diagnosis of schizophrenia, schizoaffective, schizophreniform, or bipolar I disorders\                                                                                                                                     • Age 18 to 65\                                                                                       • Duration: 16 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12\                                                    **Change in body weight**                                                             Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving OLZ for 1--24 months                                                                                                                                                                                                    • Gained ≥ 5% of body weight during first 9 months of OLZ therapy                                     • Amantadine\                                                                                                                                                                                                                                                          • **Week 16**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 100mg/day for 2 weeks then increased in 100mg/day increments to 300mg/day if deemed appropriate                                                                                                                                                                                                                                                                                                                    

  Deberdt 2008 \[[@pone.0168549.ref047]\], US                                                                                                          Examine the effects of switching from OLZ to quetiapine in obese patients with schizophrenia                                                       26 centres (n = 133)                                                                                                                             • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Age 18 to 75\                                                                                       • Duration: 24 weeks\                                                                                                                                    Care as usual: OLZ (7.5--20mg/day)                                                                            • Week 24                                                     Time to relapse                                                                       HbA~1c~ fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving fixed dose of OLZ (10--20mg/day)                                                                                                                                                                                        • BMI ≥ 30\                                                                                           • Quetiapine\                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • **or** BMI ≥ 25 and ≥ 1 CVD risk factor (including diabetes)                                        • Dose: 300--800mg/day                                                                                                                                                                                                                                                                                                                                                                                                     

  Fadai2014 \[[@pone.0168549.ref048]\] [^**o**^](#t001fn017){ref-type="table-fn"}, Iran                                                                Assess whether saffron aqueous extract (SAE) or crocin prevents OLZ induced MetS and insulin resistance in patients with schizophrenia             Inpatient ward of one psychiatric hospital (n = 66), 3 arm trial                                                                                 • DSM-IV diagnosis of schizophrenia\                                                                                                                                                                                                • Male\                                                                                               • Duration: 12 weeks\                                                                                                                                    OLZ 5--20mg/day PLUS **Placebo (Arm 3)**                                                                      • Week 2\                                                     **Presence of MetS** [^p^](#t001fn018){ref-type="table-fn"}                           HbA~1c~, **fasting glucose** [^p^](#t001fn018){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • No history of OLZ treatment                                                                                                                                                                                                       • Age 18 to 65\                                                                                       • OLZ 5--20mg/day PLUS\                                                                                                                                                                                                                                                • Week 6\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded patients with MetS                                                                         • **Arm 1: SAE**\                                                                                                                                                                                                                                                      • **Week 12**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 15mg twice daily\                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • **Arm 2: Crocin**\                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 15mg twice daily                                                                                                                                                                                                                                                                                                                                                                                                   

  Fan 2013 \[[@pone.0168549.ref049]\], US                                                                                                              Examine effects of aripiprazole on metabolic parameters in CLZ treated patients with schizophrenia                                                 Outpatients from a mental health centre (n = 38)                                                                                                 • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Age 18 to 65                                                                                        • Duration: 8 weeks\                                                                                                                                     Placebo                                                                                                       • Week 8                                                      **Glucose metabol-ism** FSIVGTT                                                       HbA~1c~, fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Treatment with CLZ for \> 1 year and stable dose                                                                                                                                                                                                                                                                                        • Aripiprazole\                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 15mg/day                                                                                                                                                                                                                                                                                                                                                                                                           

  Fleischhacker 2010 \[[@pone.0168549.ref050]\], 10 European countries and South Africa                                                                Examine effects of adjunctive aripiprazole on body weight and metabolic parameters in CLZ treated patients with schizophrenia                      Outpatients from 55 centres across countries involved (n = 207)                                                                                  • DSM-IV diagnosis of schizophrenia\                                                                                                                                                                                                • Age 18 to 65\                                                                                       • Duration: 16 weeks\                                                                                                                                    Placebo                                                                                                       • Weeks 1--4\                                                 **Change in body weight**                                                             Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving stable dose of CLZ monotherapy (200--900mg/day) ≥ 3 months (not optimally controlled)                                                                                                                                   • Experienced weight gain of ≥ 2.5kg while taking CLZ                                                 • Aripiprazole\                                                                                                                                                                                                                                                        • Week 6\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 5mg/day for 2 weeks with an option to increase to 10mg/day in weeks 2--4, and to 15mg/day after week 4                                                                                                                                                         • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • Week 12\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • **Week 16**                                                                                                                                       

  Graham 2005 \[[@pone.0168549.ref051]\], US **(excluded from met-analysis)**                                                                          Examine effects of amantadine on weight gain and metabolic profile in psychiatric patients taking OLZ                                              Outpatients from private clinics and schizophrenia treatment programme (n = 21)                                                                  • A psychiatric condition (not specified)\                                                                                                                                                                                          • Gained ≥ 5lbs while taking OLZ                                                                      • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12                                                     **BMI**                                                                               Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving OLZ treatment                                                                                                                                                                                                                                                                                                                 • Amantadine\                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: up to 300mg/day                                                                                                                                                                                                                                                                                                                                                                                                    

  Henderson 2005 \[[@pone.0168549.ref052]\], US                                                                                                        Examine effectiveness of sibutramine to attenuate OLZ induced weight gain in patients with schizophrenia                                           Outpatients from an adult clinic of an urban mental health centre (n = 37)                                                                       • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Age 18 to 65\                                                                                       • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 4\                                                     **Weight loss**                                                                       **HbA**~**1c**~, random glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Taking stable dose of OLZ ≥ 4 months                                                                                                                                                                                              • BMI ≥ 30\                                                                                           • Sibutramine\                                                                                                                                                                                                                                                         • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • **or** BMI ≥ 27 and ≥ 1 CVD risk factor (including diabetes)\                                       • Dose: Weeks 1 to 4--5mg twice daily (could be reduced to once daily in response to side effects), weeks 5 to 12---increased to 15mg/day as tolerated                                                                                                                 • **Week 12**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Henderson 2007 \[[@pone.0168549.ref053]\], US                                                                                                        Investigate efficacy of sibutramine for weight loss in CLZ treated patients with schizophrenia                                                     Outpatients from a CLZ clinic of an urban mental health centre (n = 21)                                                                          • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Age 18 to 65\                                                                                       • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12                                                     Weight loss                                                                           HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Taking stable dose of CLZ ≥ 4 months                                                                                                                                                                                              • BMI ≥ 30\                                                                                           • Sibutramine\                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • **or** BMI ≥ 27 and ≥ 1 CVD risk factor\                                                            • Dose: Weeks 1 to 4--5mg twice daily\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medications                                                                    • Weeks 5 to 12---increased to 15mg/day as tolerated (adjusted to 1--3 capsules daily)                                                                                                                                                                                                                                                                                                                                     

  Henderson 2009A \[[@pone.0168549.ref054]\] [^**q**^](#t001fn019){ref-type="table-fn"}, US                                                            Investigate effects of adjunctive aripiprazole to attenuate OLZ induced weight gain in patients with schizophrenia                                 Outpatients from an urban community mental health clinic (n = 15^s^)                                                                             • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Age 18 to 65\                                                                                       • Duration: 10 weeks\                                                                                                                                    Week 1 to 4: Placebo, Week 5 to 6: Washout, Week 7--10: Aripiprazole (15mg/day)                               **Week 4**\                                                   **Change in body weight**                                                             HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Maintained on stable dose of OLZ for ≥ 1 month                                                                                                                                                                                    • BMI ≥ 30\                                                                                           • Week 1 to 4: Aripiprazole\                                                                                                                                                                                                                                           • Week 6\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • **or** BMI ≥ 27 and ≥ 1 CVD risk factor (including diabetes)                                        • Dose: 15mg/day\                                                                                                                                                                                                                                                      • Week 10                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Week 5 to 6: Washout\                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Week 7--10: Placebo                                                                                                                                                                                                                                                                                                                                                                                                      

  Henderson 2009B \[[@pone.0168549.ref055]\], US                                                                                                       Investigate effects of rosiglitazone for CLZ induced glucose metabolism impairment in patients with schizophrenia                                  Outpatients of a mental health clinic (n = 18)                                                                                                   • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 8 weeksv\                                                                                                                                    Placebo                                                                                                       • Week 8                                                      Insulin resistance FSIVGTT                                                            HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Treated with CLZ for ≥ 1 year                                                                                                                                                                                                     • Evidence of insulin resistance or impaired glucose (≥ 110mg/dl)\                                    • Rosiglitazone\                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medications                                                                    • Dose: 4mg/day                                                                                                                                                                                                                                                                                                                                                                                                            

  Hoffmann 2012 \[[@pone.0168549.ref056]\] [^**r**^](#t001fn020){ref-type="table-fn"}, Israel, Mexico, Republic of Korea, Russian Federation, and US   Determine if OLZ induced weight gain can be managed with adjunctive treatment algorithms that include amantadine, metformin and zonisamide         Outpatients (n = 199), 3 arm trial                                                                                                               • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 22 weeks\                                                                                                                                    **Arm3:** OLZ 5--20mg/day                                                                                     • Week 22                                                     Change in body weight                                                                 **HbA**~**1c**~ [^**s**^](#t001fn021){ref-type="table-fn"}, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Patients who were treatment resistant to OLZ were excluded                                                                                                                                                                        • BMI between 20 and 35 inclusive                                                                     • OLZ 5--20mg/day PLUS:\                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • **Arm 1:** amantadine (200mg/day) with option of switching to metformin (500--1500mg/day) and then zonisamide (100--400mg/day)\                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • **Arm 2:** metformin with option of switching to amantadine & zonisamide (same doses as Arm 1)                                                                                                                                                                                                                                                                                                                           

  Holka-Pokorska \[[@pone.0168549.ref057]\], Poland                                                                                                    Evaluate the effects of a steroid hormone (DHEA) on MetS parameters in patients with schizophrenia treated with OLZ                                Setting not reported (n = 55)                                                                                                                    • ICD-10 diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Male\                                                                                               • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 12                                                     MetS criteria                                                                         **Fasting glucose**
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • No prior treatment with CLZ\                                                                                                                                                                                                      • Age 18 to 65                                                                                        • Dehydro-epiandrosterone\                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving stable dose of OLZ ≥ 6 weeks                                                                                                                                                                                                                                                                                                  • Dose: 50mg/day for first 2 weeks, then titrated up to 100mg/day for remaining weeks if tolerated                                                                                                                                                                                                                                                                                                                         

  Jarskog 2013 \[[@pone.0168549.ref058]\], US                                                                                                          Determine whether metformin promotes weight loss in overweight patients with schizophrenia                                                         Outpatients from 17 academic, VA, and private clinic mental health sites (n = 148)                                                               • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 16 weeks\                                                                                                                                    Placebo                                                                                                       • Week 16                                                     **Change in body weight**                                                             **HbA**~**1c**~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Duration of illness ≥ 1 year\                                                                                                                                                                                                     • BMI ≥ 27\                                                                                           • Metformin\                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving stable dose (\> 2 months) of no more than 2 APMs                                                                                                                                                                        • Excluded previous treatment with metformin\                                                         • Dose: 500mg twice daily increased to 1500mg/day after week 1 and to 2000mg/day at week 3                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medications in past month                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Joffe 2008 \[[@pone.0168549.ref059]\], Finland                                                                                                       Investigate effects of adjunctive orlistat to attenuate OLZ or CLZ induced weight gain in patients with SMI                                        Inpatients or outpatients (n = 71)                                                                                                               • SMI diagnosis that was relatively stable\                                                                                              Excluded patients with type 1 diabetes                                                     • Age 18 to 65vBMI between 28 and 43 inclusive\                                                       • Duration: 16 weeks\                                                                                                                                    Placebo                                                                                                       • Week 4\                                                     Change in body weight                                                                 Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving stable dose of CLZ or OLZ                                                                                                                                                                                               • Excluded patients with significant changes in body weight in last 4 weeks                           • Orlistat\                                                                                                                                                                                                                                                            • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 120mg capsule taken during the main fat-containing meals                                                                                                                                                                                                       • **Week 16**                                                                                                                                       

  Karagianis 2009 \[[@pone.0168549.ref060]\] [^**t**^](#t001fn022){ref-type="table-fn"}, Canada, Netherlands, US and Mexico                            Investigate effects of orally disintegrating OLZ to attenuate standard OLZ induced weight gain in patients with SMI                                Outpatients (n = 149)                                                                                                                            • DSM-IV diagnosis of schizophrenia, schizoaffective, schizophreniform or bipolar disorders, or other related psychotic disorder\                                                                                                   Experienced weight gain of ≥ 5kg or a change of ≥ 1 kg/m^2^ BMI\                                      • Duration: 16 weeks\                                                                                                                                    Continue with OLZ standard tablets PLUS Placebo (sublingual)                                                  • Week 16                                                     Change in BMI                                                                         HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Taking OLZ (standard tablets) (5--20mg) for between 4 and 52 weeks                                                                                                                                                                • Excluded patients using weight loss medication / programme                                          • OLZ orally disintegrating form (5--20mg) PLUS Placebo (tablet)\                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: as per previous OLZ standard treatment (5--20mg)                                                                                                                                                                                                                                                                                                                                                                   

  Kusumi 2012 \[[@pone.0168549.ref061]\], Japan                                                                                                        Investigate effects of orally disintegrating OLZ on body weight and metabolic measures in OLZ-naïve patients with schizophrenia                    Patients of 7 general, 12 psychiatric and 1 university hospital (n = 118)                                                                        • DSM-IV diagnosis of schizophrenia\                                                                                                                                                                                                                                                                                                      • Duration: 12 months\                                                                                                                                   OLZ standard tablets, dose: Flexible dose prescribed by treating psychiatrist                                 • Month 3\                                                    Change in body weight                                                                 HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Required a change in APM or new treatment with APM                                                                                                                                                                                                                                                                                      • Drug: OLZ orally disintegrating form (5--20mg)\                                                                                                                                                                                                                      • Month 6\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: Flexible dose prescribed by treating psychiatrists                                                                                                                                                                                                             • Month 12                                                                                                                                          

  Lee 2013 \[[@pone.0168549.ref062]\], Taiwan                                                                                                          Investigate effects of adjunctive memantine on metabolic parameters in patients with bipolar II disorder using valproate                           Outpatient and inpatient settings (n = 135)                                                                                                      • DSM-IV diagnosis of bipolar II disorder                                                                                                                                                                                                                                                                                                 • Duration: 12 weeks\                                                                                                                                    Valproate (500 or 1000mg/ day) PLUS Placebo                                                                   • Week 2\                                                     Psychotic symptom severity                                                            HbA~1c~, fasting serum glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Valproate (500 or 1000mg/day)vPLUS\                                                                                                                                                                                                                                  • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Memantine\                                                                                                                                                                                                                                                           • **Week 12**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 5mg/day                                                                                                                                                                                                                                                                                                                                                                                                            

  Li 2013 \[[@pone.0168549.ref063]\], US                                                                                                               Examine effect of adjunctive insulin therapy on metabolic function in patients with schizophrenia treated with APM                                 Outpatients from an urban community mental health clinic (n = 45)                                                                                • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded patients with diabetes                                                            • Age 18 to 65                                                                                        •Duration: 8 weeks\                                                                                                                                      Placebo                                                                                                       • Week 8                                                      Change in body weight                                                                 HbA~1c~, fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving stable dose of APM for ≥ 1 month                                                                                                                                                                                                                                                                                              • Intranasal insulin treatment (40IU)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 4 times daily                                                                                                                                                                                                                                                                                                                                                                                                      

  Lu 2004 \[[@pone.0168549.ref064]\], Taiwan                                                                                                           Investigate effects of adjunctive fluvoxamine to attenuate CLZ induced weight gain and metabolic abnormalities in patients with schizophrenia      Inpatients (n = 68)                                                                                                                              • DSM-IV diagnosis of schizophrenia\                                                                                                                                                                                                • Age 18 to 60                                                                                        • Duration: 12 weeks\                                                                                                                                    CLZ monotherapy, dose: ≤ 600mg/day individually titrated                                                      • Week 12\                                                    Change in body weight                                                                 **Fasting serum glucose**
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Treatment resistant to typical APMs\                                                                                                                                                                                                                                                                                                    • CLZ and fluvoxamine co-administration\                                                                                                                                                                                                                               • Body weight measured weekly                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Not receiving CLZ or other atypical APM                                                                                                                                                                                                                                                                                                 • Dose: CLZ ≤ 250mg/day (low dose) individually titrated; fluvoxamine 50mg/day                                                                                                                                                                                                                                                                                                                                             

  McElroy 2012 \[[@pone.0168549.ref065]\], US                                                                                                          Examine effects of zonisamide for attenuating OLZ induced weight gain in patients with SMI                                                         Outpatients of one mental health centre (n = 42)                                                                                                 • DSM-IV diagnosis of a psychotic or bipolar disorder for whom OLZ would be clinically indicated\                                                                                                                                   • Age ≥ 18\                                                                                           • Duration: 16 weeks\                                                                                                                                    OLZ (5--25mg/day adjusted for optimal response) PLUS Placebo                                                  • Week 16                                                     **Change in body weight**                                                             Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • No treatment with OLZ within last 3 months                                                                                                                                                                                        • BMI ≥ 22\                                                                                           • OLZ (5--25mg/day adjusted for optimal response) PLUS Zonisamide\                                                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded patients using weight loss medication                                                      • Dose: 100mg/day titirated to maximum 600mg/day over 6 weeks                                                                                                                                                                                                                                                                                                                                                              

  Modabbernia 2014 \[[@pone.0168549.ref066]\], Iran                                                                                                    Assess efficacy of melatonin for attenuating the metabolic side-effects of OLZ in patients with first-episode schizophrenia                        Patients of one academic psychiatric hospital (n = 48)                                                                                           • DSM-IV diagnosis of schizophrenia and in their first-episode of illness\                                                               Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 8 weeks\                                                                                                                                     OLZ (5mg/day titrated to 25mg/day for optimal response) PLUS Placebo                                          • Week 4\                                                     **Change in body weight**                                                             Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Eligible for OLZ treatment and no prior OLZ in last 3 months                                                                                                                                                                      • Excluded patients with MetS                                                                         • OLZ (5mg/day titrated to 25mg/day for optimal response) PLUS Melatonin\                                                                                                                                                                                              • **Week 8**                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 3mg/day                                                                                                                                                                                                                                                                                                                                                                                                            

  Narula 2010 \[[@pone.0168549.ref067]\], India                                                                                                        Assess efficacy of topiramate for preventing weight gain and metabolic side-effects of OLZ in patients with first-episode schizophrenia            Inpatients and outpatients attending the psychiatry clinic at a tertiary care hospital (n = 72)                                                  • ICD-10 diagnosis of schizophrenia\                                                                                                                                                                                                • Age 18 to 65                                                                                        • Duration: 12 weeks\                                                                                                                                    OLZ (5mg- 20mg/day titrated for optimal response) PLUS Placebo                                                • Week 12                                                     **Change in body weight**                                                             **Fasting glucose**
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • In their first-episode of illness and drug-naïve                                                                                                                                                                                                                                                                                        • OLZ (5mg-20mg/day titrated for optimal response) PLUS Topiramate\                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 50mg/day for 1 week and then 100mg/day                                                                                                                                                                                                                                                                                                                                                                             

  Newcomer 2008 \[[@pone.0168549.ref068]\], Multi-national                                                                                             Examine effects of switching from OLZ to aripiprazole on metabolic parameters in overweight patients with schizophrenia                            Multi-centre (n = 173)                                                                                                                           • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                         Excluded patients with diabetes                                                            • Age 18 to 65\                                                                                       • Duration: 16 weeks\                                                                                                                                    Care as usual: OLZ (same dose for 4 weeks then dosed at 10--20mg/day for optimal response)                    • Week 4\                                                     **Change in body weight**                                                             Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving OLZ monotherapy (10--20mg/day) at screening, for between 1 and 24 months                                                                                                                                                • BMI ≥ 27\                                                                                           • Aripiprazole\                                                                                                                                                                                                                                                        • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Weight gain during OLZ treatment verified\                                                          • Dose: Titrated to 15mg/day over 2 weeks with down-titration of OLZ treatment; after 4 weeks flexible dosed at 10--30mg/day for optimal response                                                                                                                      • Week 12\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded patients who lost \> 10% of body weight in last 3 months                                                                                                                                                                                                                                                                                                          • **Week 16**                                                                                                                                       

  Smith2013 \[[@pone.0168549.ref069]\] [^**u**^](#t001fn023){ref-type="table-fn"}, US and China                                                        Examine effects of pioglitazone on metabolic abnormalities in patients with schizophrenia treated with APM                                         4 sites in US and 1 site in China (n = 56)                                                                                                       • DSM-IV diagnosis of schizophrenia or schizoaffective disorder (chronic)\                                                               Impaired fasting glucose (≥ 100mg/dl) or current treatment with anti-diabetic medication   • Impaired lipids (triglycerides ≥ 120mg/dl and/or HDL \<40mg/dL)                                     • Duration: 3 months\                                                                                                                                    Placebo                                                                                                       • Month 1\                                                    **Fasting glucose**[^**v**^](#t001fn024){ref-type="table-fn"}                         HbA~1c~, **fasting glucose**[^**v**^](#t001fn024){ref-type="table-fn"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Currently treated with any APM                                                                                                                                                                                                                                                                                                          • Pioglitazone\                                                                                                                                                                                                                                                        • Month 2\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 30mg/day with permission to raise to 45mg/day if glucose control was deemed insufficient                                                                                                                                                                       • **Month 3**                                                                                                                                       

  Stroup 2011 \[[@pone.0168549.ref070]\], US                                                                                                           Examine efficacy of switching from OLZ, quetiapine or risperidone to aripiprazole for ameliorating metabolic risk in patients with schizophrenia   27 clinical research centres affiliated with the Schizophrenia Trials Network (US) (n = 215)                                                     • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • BMI ≥ 27\                                                                                           • Duration: 24 weeks\                                                                                                                                    Care as usual: OLZ, quetiapine or risperidone continued at previous dose                                      • Week 4\                                                     **Non-HDL-C**                                                                         HbA~1c~, fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Stable dose of OLZ (5--20mg), quetiapine (200--1200mg) or risperidone (1--16mg) ≥ 3 months                                                                                                                                        • Impaired lipids (non-HDL cholesterol ≥ 130mg/dl)\                                                   • Aripiprazole\                                                                                                                                                                                                                                                        • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Desire to improve metabolic risk profile                                                            • Dose: 5mg/day in week 1; 10mg/day in week 2; 10--15mg/day in week 3; optimised to 5--30mg/day from week 4\                                                                                                                                                           • Week 12\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Previous APM was removed over 4 weeks                                                                                                                                                                                                                                • Week 16\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • Week 20\                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            • **Week 24**                                                                                                                                       

  Tek 2014 \[[@pone.0168549.ref071]\], US                                                                                                              Examine effects of adjunctive naltrexone to counteract APM-associated weight gain in patients with schizophrenia                                   Setting not reported (n = 24)                                                                                                                    • DSM-IV diagnosis of schizophrenia or schizoaffective disorder\                                                                                                                                                                    • Female\                                                                                             • Duration: 8 weeks\                                                                                                                                     Placebo                                                                                                       • Week 8                                                      **Change in body weight**                                                             HbA~1c~, random glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving stable dose of APM                                                                                                                                                                                                      • Age 18 to 70\                                                                                       • Naltrexone\                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • BMI ≥ 27 and \>2% of body weight gain in last year\                                                 • Dose: 25mg/day                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               • Excluded weight loss medications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Wang 2012 \[[@pone.0168549.ref072]\], China                                                                                                          Evaluate efficacy of metformin for treatment of APM induced weight gain in patients with first-episode schizophrenia                               Outpatients of a schizophrenia clinic in two hospitals (n = 72)                                                                                  • DSM-IV diagnosis of schizophrenia and in first-episode of illnessvReceiving stable dose of only one APM\                               Excluded patients with diabetes                                                            • Age 18 to 60\                                                                                       • Duration: 12 weeks\                                                                                                                                    Placebo                                                                                                       • Week 4\                                                     **Change in body weight**                                                             Fasting glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Have been treated with OLZ, sulpiride, CLZ, or risperidone                                                                                                                                                                        • Gained \>7% of body weight in first year of being treated with OLZ, CLZ, risperidone or sulpiride   • Metformin\                                                                                                                                                                                                                                                           • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 250mg twice daily for 3 days increased to 500mg twice daily (1000mg/day) for remaining period                                                                                                                                                                  • **Week 12**                                                                                                                                       

  Wani 2015 \[[@pone.0168549.ref073]\], India                                                                                                          Examine efficacy of switching from OLZ to aripiprazole to improve metabolic profile of patients with schizophrenia and MetS                        Outpatients of a tertiary care psychiatry hospital (n = 62)                                                                                      • DSM-IV diagnosis of schizophrenia\                                                                                                                                                                                                • Fulfilling criteria for presence of MetS\                                                           • Duration: 24 weeks\                                                                                                                                    Care as usual: OLZ (previous dose)                                                                            • Week 8\                                                     **Presence of MetS**                                                                  Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Achieved clinical stability with OLZ\                                                                                                                                                                                             • Desire to improve their metabolic risk profile                                                      • Aripiprazole\                                                                                                                                                                                                                                                        • **Week 24**                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • Receiving OLZ (10--20mg/day) for ≥ 3 months with no other APM for ≥ 1 month                                                                                                                                                                                                                                                             • Dose: 5mg/day in week 1; 10mg/day in week 2; 10--15mg/day in week 3; 10--20mg/day in week 4 and 10--30mg/day from week 5\                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • OLZ removed over 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                 

  Wu 2008B \[[@pone.0168549.ref074]\], China                                                                                                           Assess efficacy of metformin to prevent OLZ induced weight gain in drug-naïve patients with schizophrenia                                          New inpatients (first episode) at one hospital (n = 40)                                                                                          • DSM-IV diagnosis of schizophrenia and in first-episode of illness\                                                                     Excluded patients with diabetes                                                            • Age 18 to 50                                                                                        • Duration: 12 weeks\                                                                                                                                    OLZ (15mg/day) PLUS Placebo                                                                                   • Week 4\                                                     **Change in body weight**                                                             Fasting plasma glucose
                                                                                                                                                                                                                                                                                                                                                                                                                                                           • No APM usage for at least 3 months                                                                                                                                                                                                                                                                                                      • OLZ (15mg/day) PLUS Metformin\                                                                                                                                                                                                                                       • Week 8\                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     • Dose: 250mg three times daily (750mg/day)                                                                                                                                                                                                                            • **Week 12**                                                                                                                                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table footnotes:

Abbreviations: APM = antipsychotic medication; ARIP = aripiprazole; BMI = body mass index (kg/m^2^); CLZ = clozapine; CV = cardiovascular; CVD = cardiovascular disease; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4^th^ Edition; FSIVGTT = frequently sampled intravenous glucose tolerance test; HbA~1c~ = glycated haemoglobin; HDL = high-density lipoprotein; ICD-10 = International Statistical Classification of Diseases and Related Health Problems, 10^th^ Revision; kg = kilograms; m = metre; MetS = metabolic syndrome; MH = mental health; MHP = mental health professional; non-HDL-C = total cholesterol minus high-density lipoprotein; NR = not reported; OGTT = oral glucose tolerance test; OLZ = olanzapine; OT = Occupational Therapist; PPA = phenylpropanolamine; SAE = saffron aqueous extract; SMI = severe / serious mental illness; ZIP = ziprasidone

^a^ Follow-up highlighted in bold is end of intervention follow-up and is the time point used for the meta-analyses

^b^ Outcomes highlighted in bold indicate statistically significant improvement for intervention compared to control

^c^ Attux 2013: results for change in body weight only significant at 6 months

^d^ Cordes 2014: results for body weight only significant for % change; results for fasting glucose and OGTT only significant at 48 weeks

^e^ Daumit 2013: no p-value or indication of statistical significance provided

^f^ Forsberg 2008: cluster design including staff and patient participants--patient data used for meta-analysis

^g^ Gillhoff 2010: results for BMI only significant in women

^h^ Mauri 2008: intervention participants receive intervention for full 24 weeks, control participants receive intervention in weeks 13 to 24 --data collected at week 12 used for meta-analysis

^i^ Poulin 2007: no data or results reported for HbA~1c~

^j^ Weber 2006: no data or results reported for fasting glucose because of problems obtaining data

^k^ Wu 2008: data were used in both meta-analyses--for pharmacological interventions we combined the metformin arms and compared these to the placebo arms; for behavioural interventions we compared the lifestyle plus placebo arm to the placebo arm

^l^ Amrami-Weizman 2013: data pooled from two trials, however trials were identical in design and conduct

^m^ Borovicka 2002: no data or results reported for HbA~1c~

^n^ Chen 2012: this study included two similar interventions and no control group and was therefore excluded from the meta-analysis

^o^ Fadai 2014: the two intervention arms were pooled for the meta-analysis due to the same mechanism of action

^p^ Fadai 2014: both arms were superior to placebo

^q^ Henderson 2009A: cross-over design--data from week 4 used for meta-analysis (before cross-over)

^r^ Hoffmann 2012: the two intervention arms were pooled for the meta-analysis due to the same mechanism of action

^s^ Hoffmann 2012: only arm B was superior to the control intervention

^t^ Karagianis 2009: standard deviation for mean change scores were imputed from Kusumi 2012 because of data error

^u^ Smith 2013: the US and China sites were separated for the meta-analysis due to conflicting results (paper reports US results only)

^v^ Smith 2013: significance refers to findings from US sites

Participants {#sec008}
------------

There were a total of 4,392 participants; 2,315 were assigned to intervention and 2,077 to control arms.

Participants were mainly drawn from mental health outpatient and inpatient settings (n = 47 studies). One study recruited from supported housing schemes \[[@pone.0168549.ref024]\], and one from residential care facilities and day programmes \[[@pone.0168549.ref029]\]. Five studies did not report setting \[[@pone.0168549.ref047], [@pone.0168549.ref057], [@pone.0168549.ref068], [@pone.0168549.ref069], [@pone.0168549.ref071]\].

All but three studies \[[@pone.0168549.ref048], [@pone.0168549.ref057], [@pone.0168549.ref071]\] included both men and women, although overall women were under-represented (41%). Mean age ranged from 25 to 53 years, with a mean age across studies of 43 years. Ethnicity was poorly recorded, but varied significantly due to the range of countries included.

Eighteen studies recruited participants with schizophrenia; 20 with schizophrenia and schizoaffective disorder; two with bipolar disorder; and 14 with various SMIs. The majority of studies included clinically stable participants who had been diagnosed for several years.

Inclusion of participants with diabetes varied. Only one study specifically recruited people with type 2 diabetes \[[@pone.0168549.ref029]\]. Twenty-three studies excluded participants with diabetes (one excluded type 1 diabetes \[[@pone.0168549.ref059]\]). The remaining studies did not specify this in eligibility criteria. Mean HbA~1c~ at baseline ranged from 4.1% to 7.4% (n = 26 studies); 13 studies reported a mean in the American Diabetes Association (ADA) pre-diabetes category (5.7--6.4%) and two in the diabetes range (≥6.5%). Mean fasting glucose ranged from 4.3 to 6.8mmol/L (n = 43 studies); 14 studies reported a baseline mean in the ADA high risk category (5.6--6.9mmol/L) \[[@pone.0168549.ref075]\].

Thirty studies targeted overweight participants or those who had experienced significant weight gain. Mean BMI at baseline ranged from 20.2 to 41.9Kg/m^2^ (n = 49 studies); 41 studies reported a mean BMI of over 25Kg/m^2^.

Interventions {#sec009}
-------------

Of the 54 RCTs identified, 40 assessed a pharmacological, 13 a non-pharmacological and one a mixed intervention.

Among the pharmacological studies, 32 used a placebo in the control arm \[[@pone.0168549.ref035]--[@pone.0168549.ref043], [@pone.0168549.ref045], [@pone.0168549.ref046], [@pone.0168549.ref048]--[@pone.0168549.ref055], [@pone.0168549.ref057]--[@pone.0168549.ref060], [@pone.0168549.ref062], [@pone.0168549.ref063], [@pone.0168549.ref065]--[@pone.0168549.ref067], [@pone.0168549.ref069], [@pone.0168549.ref071], [@pone.0168549.ref072], [@pone.0168549.ref074]\]. Seven trials evaluated an intervention against usual care \[[@pone.0168549.ref047], [@pone.0168549.ref056], [@pone.0168549.ref061], [@pone.0168549.ref064], [@pone.0168549.ref068], [@pone.0168549.ref070], [@pone.0168549.ref073]\]. One study compared two interventions but did not include a control arm \[[@pone.0168549.ref044]\].

Among the non-pharmacological studies, six compared an intervention with usual care \[[@pone.0168549.ref021], [@pone.0168549.ref022], [@pone.0168549.ref025], [@pone.0168549.ref027], [@pone.0168549.ref030], [@pone.0168549.ref032]\], and three provided basic information or advice to controls at baseline \[[@pone.0168549.ref023], [@pone.0168549.ref026], [@pone.0168549.ref029]\]. In one study, the intervention was also given to the control group after week 12 of 24 weeks \[[@pone.0168549.ref028]\]. Two studies included an active control arm \[[@pone.0168549.ref024], [@pone.0168549.ref031]\]. One trial did not describe the control intervention \[[@pone.0168549.ref033]\].

The mixed intervention study included four arms: metformin, metformin plus a lifestyle intervention, lifestyle plus placebo, and a control arm receiving placebo alone \[[@pone.0168549.ref034]\].

### Pharmacological interventions {#sec010}

In total, 23 different medications from 15 categories of drug were evaluated (see [Table 2](#pone.0168549.t002){ref-type="table"}).

10.1371/journal.pone.0168549.t002

###### Pharmacological Intervention Categories.

![](pone.0168549.t002){#pone.0168549.t002g}

  Category and drugs                                                                                                                                                                                                                                                                                                                  Mechanism of action
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Diabetes medication n = 12 \[[@pone.0168549.ref034], [@pone.0168549.ref036], [@pone.0168549.ref037], [@pone.0168549.ref039], [@pone.0168549.ref043], [@pone.0168549.ref045], [@pone.0168549.ref055], [@pone.0168549.ref058], [@pone.0168549.ref063], [@pone.0168549.ref069], [@pone.0168549.ref072], [@pone.0168549.ref074]\]**   
  Insulin                                                                                                                                                                                                                                                                                                                             Diabetes treatment used to regulate carbohydrate and fat metabolism in the body.
  Metformin                                                                                                                                                                                                                                                                                                                           A biguanide used to prevent and treat Type 2 diabetes by increasing insulin sensitivity and reducing the amount of glucose produced and released by the liver.
  Pioglitazone, Rosiglitazone                                                                                                                                                                                                                                                                                                         Thiazolidinediones help to regulate glucose and fat metabolism by improving insulin sensitivity, allowing insulin to work more effectively. Rosiglitazone has been withdrawn from the EU.
  **Weight loss medication n = 9 \[[@pone.0168549.ref035], [@pone.0168549.ref040], [@pone.0168549.ref046], [@pone.0168549.ref051]--[@pone.0168549.ref053], [@pone.0168549.ref059], [@pone.0168549.ref065], [@pone.0168549.ref067]\]**                                                                                                 
  Amantadine                                                                                                                                                                                                                                                                                                                          A dopamine agonist approved to treat extrapyramidal side effects and parkinsonian, with potential to decrease prolactin (plays a role in metabolism) or to decrease appetite.
  Orlistat                                                                                                                                                                                                                                                                                                                            An anti-obesity drug which acts on the gastro-intestinal tract by reducing absorption of dietary fat.
  Reboxetine                                                                                                                                                                                                                                                                                                                          An anti-depressant, believed to promote weight loss by inhibiting serotonin re-uptake and by doing so regulate eating behaviour and appetite control.
  Sibutramine                                                                                                                                                                                                                                                                                                                         A centrally acting appetite suppressant which has been withdrawn from the UK and other countries.
  Topiramate, Zonisamide                                                                                                                                                                                                                                                                                                              Anticonvulsant (epileptic) medication believed to promote weight loss by stimulating energy expenditure and decreasing body fat stores (by inhibiting carbonic anhydrase).
  **Weight loss and diabetes combination n = 2 \[[@pone.0168549.ref038], [@pone.0168549.ref056]\]**                                                                                                                                                                                                                                   
  Amantadine + metformin + zonisamide, Metformin + amantadine + zonisamide                                                                                                                                                                                                                                                            Treatment algorithms of anti-diabetic, anti-parkinsonian and anti-epileptic medications to allow patients to switch between treatments depending on clinical response.
  Metformin + sibutramine                                                                                                                                                                                                                                                                                                             Adding an appetite suppressant to an anti-diabetic may enhance weight loss potential.
  **Antipsychotic switching n = 10 \[[@pone.0168549.ref044], [@pone.0168549.ref047], [@pone.0168549.ref049], [@pone.0168549.ref050], [@pone.0168549.ref054], [@pone.0168549.ref060], [@pone.0168549.ref061], [@pone.0168549.ref068], [@pone.0168549.ref070], [@pone.0168549.ref073]\]**                                               
  Aripiprazole, Quetiapine, Ziprasidone                                                                                                                                                                                                                                                                                               Switching to or adding an atypical antipsychotic associated with fewer metabolic side effects is hypothesised to alleviate weight gain and metabolic abnormalities caused by the more commonly used antipsychotics like olanzapine and clozapine.
  Olanzapine orally disintegrating                                                                                                                                                                                                                                                                                                    The orally disintegrating form of olanzapine is argued to induce fewer metabolic side effects than the standard tablet.
  **Other n = 8 \[[@pone.0168549.ref041], [@pone.0168549.ref042], [@pone.0168549.ref048], [@pone.0168549.ref057], [@pone.0168549.ref062], [@pone.0168549.ref064], [@pone.0168549.ref066], [@pone.0168549.ref071]\]**                                                                                                                  
  Crocin, Saffron aqueous extract (SAE)                                                                                                                                                                                                                                                                                               Herbal extracts with the potential to enhance lipid profile and metabolic function. Crocin is the active ingredient of SAE.
  Dehydroepiandrosterone (DHEA)                                                                                                                                                                                                                                                                                                       A steroid hormone with systemic anti-atherosclerotic properties which help to increase insulin sensitivity and prevent development of metabolic syndrome components.
  Fluvoxamine                                                                                                                                                                                                                                                                                                                         An anti-depressant used in combination with clozapine could help to reduce clozapine dose thereby alleviating APM induced weight gain and metabolic side effects.
  Melatonin, Ramelteon                                                                                                                                                                                                                                                                                                                Hypnotics used to treat insomnia which act on the circadian rhythm (normal sleep-wake cycle) and are believed to be important metabolic regulators.
  Memantine                                                                                                                                                                                                                                                                                                                           Used to treat dementia, memantine has an anti-depressant like and mood stabilizing effect and is believed to reduce binge eating episodes and weight.
  Naltrexone                                                                                                                                                                                                                                                                                                                          An opioid receptor antagonist believed to promote weight loss by altering the food reward system disturbed by APM treatment, in particular decreasing craving for sweet foods.
  Phenylpropanolamine (PPA)                                                                                                                                                                                                                                                                                                           A stimulant used as a decongestant and anorectic agent which has been withdrawn from the UK and other countries. Its anorexiant actions are thought promote weight loss.

In nine studies, all participants in intervention and control arms were also enrolled onto a lifestyle programme \[[@pone.0168549.ref038], [@pone.0168549.ref039], [@pone.0168549.ref044], [@pone.0168549.ref051]--[@pone.0168549.ref053], [@pone.0168549.ref058], [@pone.0168549.ref069], [@pone.0168549.ref070]\]. In seven further studies all participants had lifestyle advice at baseline \[[@pone.0168549.ref043], [@pone.0168549.ref045], [@pone.0168549.ref046], [@pone.0168549.ref056]\], personal wellness counselling \[[@pone.0168549.ref065]\], limited dietary intake \[[@pone.0168549.ref074]\], or mandatory monthly dietary counselling \[[@pone.0168549.ref042]\]. Details of these interventions and levels of engagement were not reported.

Intervention duration varied from four weeks to 12 months, being 6 months or less in most studies.

### Non-pharmacological interventions {#sec011}

All 14 non-pharmacological interventions targeted change in individual behaviour rather than organisation of care. Interventions were variously described as lifestyle interventions, weight loss programmes and physical exercise programmes; however, there was considerable overlap between these categories. In total, eight interventions included regular exercise sessions \[[@pone.0168549.ref023]--[@pone.0168549.ref025], [@pone.0168549.ref027], [@pone.0168549.ref030], [@pone.0168549.ref031], [@pone.0168549.ref033], [@pone.0168549.ref034]\] and three restricted calorie intake \[[@pone.0168549.ref028], [@pone.0168549.ref033], [@pone.0168549.ref034]\]. All but one intervention \[[@pone.0168549.ref031]\] included dietary recommendations, and all but two \[[@pone.0168549.ref031], [@pone.0168549.ref033]\] employed educational and behavioural strategies promoting a healthier lifestyle.

Staff delivering interventions varied, but the majority were mental health staff. No intervention specifically included carers of participants, although in one, carers were invited to join a session \[[@pone.0168549.ref021]\].

Intervention duration varied from 12 weeks to 18 months, with the majority being between 4 and 6 months. Group sessions were provided in 12 interventions, 4 of which also included individual sessions or follow-up calls. Sessions varied from 30 minutes to 2 hours in length, with frequency ranging from 3-times weekly to once a month.

Outcomes {#sec012}
--------

Our primary outcomes of interest were HbA~1c~ and fasting glucose.

Nineteen pharmacological studies measured both of these outcomes. A further five measured HbA~1c~ (one did not provide data) \[[@pone.0168549.ref042]\], and 16 measured fasting glucose (one did not provide data \[[@pone.0168549.ref051]\] and one provided dichotomous data that were not useable in meta-analysis \[[@pone.0168549.ref046]\]).

Three behavioural studies measured both HbA~1c~ and fasting glucose \[[@pone.0168549.ref024], [@pone.0168549.ref029], [@pone.0168549.ref030]\]. One of these did not provide data for HbA~1c~ \[[@pone.0168549.ref030]\], and one reported log transformed data for fasting glucose which were not useable in meta-analysis \[[@pone.0168549.ref029]\]. One study measured HbA~1c~ only \[[@pone.0168549.ref025]\], and the other nine studies measured fasting glucose only (one did not provide data \[[@pone.0168549.ref032]\] and one provided dichotomous data that were not useable \[[@pone.0168549.ref026]\]).

The mixed intervention study only measured fasting glucose.

All studies measured HbA~1c~ and/ or fasting glucose at the end of the intervention period. Details of the primary outcomes and follow-up period for each study are shown in [Table 1](#pone.0168549.t001){ref-type="table"}.

Risk of bias {#sec013}
------------

The risk of bias assessment for each study is provided in [S2 Table](#pone.0168549.s004){ref-type="supplementary-material"}. Only one study was assessed as low risk across all domains \[[@pone.0168549.ref074]\]. Reporting of trial design was limited in many studies. Attrition was a particular problem for behavioural interventions and also for antipsychotic switching trials, many of which reported higher discontinuation rates in the intervention compared to control groups.

Effectiveness of interventions {#sec014}
------------------------------

For HbA~1c~, six of 28 (five pharmacological and one behavioural), and for fasting glucose, nine of 48 studies (five pharmacological, three behavioural and one mixed intervention) showed improvement in the intervention group compared to the control interventions. The remainder reported no difference between groups (see [Table 1](#pone.0168549.t001){ref-type="table"}).

Meta-analysis {#sec015}
-------------

In the 48 trials included, there were a total of 4,052 participants; 2,150 were assigned to intervention and 1,902 to control arms.

### Pharmacological interventions {#sec016}

For pharmacological interventions, we pooled data from 22 studies for HbA~1c~ (n = 1515) and 34 for fasting glucose (n = 2536) (see [Fig 2](#pone.0168549.g002){ref-type="fig"}).

![Meta-analysis of pharmacological interventions.](pone.0168549.g002){#pone.0168549.g002}

For HbA~1c~ there was no evidence of a difference between the intervention and control groups (MD = -0.03%; 95% Confidence Interval (CI) \[-0.12, 0.06\]; p = 0.52). Results, however, were heterogeneous (I^2^ = 69%).

For fasting glucose there was a small but statistically significant improvement of -0.11mmol/L (95% CI, \[-0.19, -0.02\]; p = 0.02) for the intervention group compared to controls. Again, there was heterogeneity (I^2^ = 57%). Investigation of baseline imbalance (see [S1 Fig](#pone.0168549.s005){ref-type="supplementary-material"}) showed that the control group had slightly lower levels of fasting glucose (MD = 0.07mmol/L; 95% CI, \[0.01, 0.14\]; p = 0.03), a difference that while statistically significant, was very small, and if anything would lead to underestimation of the overall effect size.

For subgroup analysis of pharmacological interventions, we used the drug type categories described earlier (see [Table 2](#pone.0168549.t002){ref-type="table"}). For the 'diabetes medication' category, we further subdivided interventions into 'metformin' and 'other diabetes' treatment. Meta-analysis (see [Table 3](#pone.0168549.t003){ref-type="table"}) showed that antipsychotic switching (MD = -0.11%; 95% CI, \[-0.18, -0.05\]; p = 0.001; I^2^ = 0%) and metformin (MD = -0.08; 95% CI, \[-0.14, -0.03\]; p = 0.004; I^2^ = 0%) were effective in lowering HbA~1c~ compared to placebo or usual care, albeit with modest effect sizes. For fasting glucose, only metformin was effective (MD = -0.15mmol/L; 95% CI, \[-0.29, -0.01\]; p = 0.04; I^2^ = 51%).

10.1371/journal.pone.0168549.t003

###### Results of Subgroup Analyses.

![](pone.0168549.t003){#pone.0168549.t003g}

  Subgroup analysis                                                       Number of studies   Meta-analysis   Heterogeneity                                     
  ----------------------------------------------------------------------- ------------------- --------------- --------------- ------- ------ ------------- ---- ---------
  **PHARMACOLOGICAL INTERVENTION SUBGROUP ANALYSES**                                                                                                            
  **Intervention categories--HbA**~**1c**~ **(%)**                                                                                                              
  Metformin                                                               3                   -0.08           -0.14           -0.03   0.03   **0.004**     0    0.81
  Other diabetes medications                                              5                   0.15            -0.22           0.53    0.19   0.42          78   0.001
  Weight loss medications                                                 3                   -0.32           -0.84           0.20    0.27   0.22          86   0.001
  Antipsychotic switching                                                 6                   -0.11           -0.18           -0.05   0.03   **0.001**     0    0.86
  Weight loss and diabetes combinations                                   2                   -0.02           -0.24           0.20    0.11   0.84          8    0.30
  **Intervention categories--fasting blood glucose (mmol/L)**                                                                                                   
  Metformin                                                               8                   -0.15           -0.29           -0.01   0.07   **0.04**      51   0.04
  Other diabetes medications                                              5                   -0.06           -0.44           0.33    0.20   0.78          45   0.12
  Weight loss medications                                                 5                   -0.06           -0.44           0.32    0.19   0.77          79   0.001
  Antipsychotic switching                                                 9                   -0.04           -0.20           0.12    0.08   0.62          45   0.07
  Weight loss and diabetes combinations                                   2                   0.04            -0.47           0.56    0.26   0.87          83   0.02
  **Exclusion of people with diabetes--HbA1c (%)**                                                                                                              
  ***All pharmacological interventions*:**                                                                                                                      
  excluding people with diabetes                                          9                   0.14            -0.04           0.32    0.09   0.13          76   \<0.001
  not excluding people with diabetes                                      14                  -0.11           -0.21           -0.01   0.05   **0.04**      59   0.003
  ***Diabetes medication interventions (including metformin)*:**                                                                                                
  excluding people with diabetes                                          5                   0.18            -0.14           0.50    0.17   0.27          87   \<0.001
  not excluding people with diabetes                                      3                   -0.11           -0.31           0.09    0.10   0.29          26   0.26
  **Exclusion of people with diabetes--fasting blood glucose (mmol/L)**                                                                                         
  ***All pharmacological interventions*:**                                                                                                                      
  excluding people with diabetes                                          19                  -0.08           -0.18           0.01    0.05   0.09          52   0.004
  not excluding people with diabetes                                      16                  -0.14           -0.31           0.03    0.09   0.12          64   \<0.001
  ***Diabetes medication interventions (including metformin)*:**                                                                                                
  excluding people with diabetes                                          10                  -0.12           -0.26           0.02    0.07   0.08          53   0.02
  not excluding people with diabetes                                      3                   -0.30           -1.12           0.52    0.42   0.48          50   0.13
  ***Weight loss medication interventions*:**                                                                                                                   
  excluding people with diabetes                                          2                   0.13            -0.08           0.34    0.11   0.21          0    0.48
  not excluding people with diabetes                                      3                   -0.23           -0.77           0.30    0.27   0.39          66   0.05
  ***Antipsychotic switching interventions*:**                                                                                                                  
  excluding people with diabetes                                          2                   -0.04           -0.33           0.24    0.15   0.78          56   0.13
  not excluding people with diabetes                                      7                   -0.04           -0.25           0.17    0.11   0.71          51   0.06
  **BEHAVIOURAL INTERVENTION SUBGROUP ANALYSES**                                                                                                                
  **Intervention duration--fasting blood glucose (mmol/L)**                                                                                                     
  Short interventions (6 months or less)                                  6                   -0.23           -0.34           -0.12   0.06   **\<0.001**   0    0.56
  Long interventions (longer than 6 months)                               4                   -0.50           -0.74           -0.25   0.13   **\<0.001**   31   \<0.001
  **Repeated physical activity--fasting blood glucose (mmol/L)**                                                                                                
  Interventions with repeated physical activity                           7                   -0.33           -0.52           -0.14   0.10   **0.001**     55   0.04
  Interventions with no physical activity                                 3                   -0.11           -0.36           0.14    0.13   0.40          0    0.85
  **Exclusion of people with diabetes--fasting blood glucose (mmol/L)**                                                                                         
  Studies excluding people with diabetes                                  3                   -0.28           -0.40           -0.15   0.06   **\<0.001**   0    0.70
  Studies not excluding people with diabetes                              7                   -0.28           -0.53           -0.03   0.13   **0.03**      61   0.02

Table footnotes:

^**a**^ p-values highlighted in bold indicate statistically significant effects at the 0.05 level.

Subgroup analyses of studies that excluded participants with diabetes at baseline, and those that did not, showed that pharmacological interventions were effective in lowering HbA~1c~ only in the mixed population (MD = -0.11%; 95% CI, \[-0.21, -0.01\]; p = 0.04; I^2^ = 59%). For fasting glucose, neither group showed a statistically significant improvement compared to controls ([Table 3](#pone.0168549.t003){ref-type="table"}). The meta-regression found no association between baseline HbA~1c~ or fasting glucose levels and effect size (see [S3 Fig](#pone.0168549.s007){ref-type="supplementary-material"}).

To explore this further, we repeated the subgroup analysis for certain categories of pharmacological interventions: diabetes medication, weight loss medication and antipsychotic switching for fasting glucose; and diabetes medication for HbA~1c~. No group showed statistically significant improvements compared to controls ([Table 3](#pone.0168549.t003){ref-type="table"}). We observed larger effect sizes in studies that did not exclude diabetes at baseline for the diabetes medication and weight loss medication categories, but similar effects for antipsychotic switching ([Table 3](#pone.0168549.t003){ref-type="table"}). We did not have sufficient data to examine the remaining categories.

### Behavioural interventions {#sec017}

For behavioural interventions, we pooled data from three studies for HbA~1c~ (n = 140) and 10 for fasting glucose (n = 956) (see [Fig 3](#pone.0168549.g003){ref-type="fig"}).

![Meta-analysis of behavioural interventions.](pone.0168549.g003){#pone.0168549.g003}

Behavioural interventions were not found to be effective in lowering HbA~1c~, (MD = 0.18%; 95% CI, \[-0.07, 0.42\]; p = 0.16).

For fasting glucose, there was evidence of a difference of -0.28mmol/L (95% CI, \[-0.43, -0.12\]; p\<0.001) comparing behavioural interventions with controls. Although there was evidence of heterogeneity (I^2^ = 46%), 7 of the 10 studies favoured the intervention. Investigation of baseline imbalance (see [S2 Fig](#pone.0168549.s006){ref-type="supplementary-material"}) showed that controls had slightly lower levels of fasting glucose (MD = 0.10mmol/L; 95% CI, \[-0.02, 0.23\]; p = 0.10).

For subgroup analysis and meta-regression of behavioural interventions, we only examined fasting glucose due to the small number of studies measuring HbA~1c~. Participants receiving an intervention that included physical activity showed an improvement in fasting glucose of -0.33mmol/L (95% CI, \[-0.52, -0.14\]; p = 0.001; I^2^ = 55%) compared to usual care (see [Table 3](#pone.0168549.t003){ref-type="table"}). Participants receiving an intervention for 6 months or less had lower fasting glucose compared to usual care (MD = 0.23mmol/L; 95% CI, \[-0.34, -0.12\]; p\<0.001; I^2^ = 0%); interventions of more than 6 months duration showed an even greater effect, lowering fasting glucose by 0.50mmol/L (95% CI, \[-0.74, -0.25\]; p\<0.001; I^2^ = 31%), ([Table 3](#pone.0168549.t003){ref-type="table"}). The meta-regression (see [S4 Fig](#pone.0168549.s008){ref-type="supplementary-material"}) confirmed that interventions of a longer duration had a greater effect on fasting glucose compared to usual care (coefficient = -0.006; 95% CI, \[-0.01, -0.002\]; p = 0.007).

Subgroup analysis of studies that excluded (MD = -0.28mmol/L; 95% CI, \[-0.40, -0.15\]; p\<0.001; I^2^ = 0%) or did not exclude people with diabetes at baseline (MD = -0.28mmol/L; 95% CI, \[-0.53, -0.03\]; p = 0.03; I^2^ = 61%) showed similar statistically significant effects of behavioural interventions in improving fasting glucose compared to controls ([Table 3](#pone.0168549.t003){ref-type="table"}). However, the meta-regression ([S4 Fig](#pone.0168549.s008){ref-type="supplementary-material"}) showed that effect size increased with higher baseline fasting glucose, suggesting that interventions may be more effective in those with poorer glycaemic control (coefficient = -0.36; 95% CI, \[-0.59, -0.13\]; p = 0.002).

Sensitivity analyses {#sec018}
--------------------

Leave-one-out analyses showed that no single study had a disproportionate effect on each of the main meta-analyses. However, funnel plots showed some asymmetry (see [Fig 4](#pone.0168549.g004){ref-type="fig"}), suggesting potential publication bias for both the behavioural and pharmacological literature.

![Funnel plots of behavioural and pharmacological studies.](pone.0168549.g004){#pone.0168549.g004}

The trim-and-fill analysis suggests there is some evidence of missing studies (shown as black on the funnel plots in [Fig 4](#pone.0168549.g004){ref-type="fig"}).The adjusted effect sizes, accounting for publication bias are presented in [Table 4](#pone.0168549.t004){ref-type="table"}. Publication bias adjusted effect sizes suggest that pharmacological interventions reduce both HbA~1c~ and fasting glucose, and behavioural interventions are effective in reducing fasting glucose but not HbA~1c~.

10.1371/journal.pone.0168549.t004

###### Results of Trim-and-fill Analysis.
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  Analysis                     Number of studies                          Meta-analysis                                 Trim-and-fill effect size (95% CI) \[adjusted studies\]   I^2^                                                        
  ---------------------------- ------------------------------------------ --------------------------------------------- --------------------------------------------------------- ------- --------------------------------------------------- -----
  **Behavioural**                                                                                                                                                                                                                             
  *HbA*~*1c*~ *(%)*            3                                          0.18                                          -0.07                                                     0.42    0.20 (-0.01 to 0.41) \[[@pone.0168549.ref005]\]     0%
  *Fasting glucose (mmol/L)*   10                                         -0.28[^b^](#t004fn003){ref-type="table-fn"}   -0.43                                                     -0.12   -0.32 (-0.46 to -0.17) \[[@pone.0168549.ref012]\]   46%
  **Pharmacological**                                                                                                                                                                                                                         
  *HbA*~*1c*~ *(%)*            23[^a^](#t004fn002){ref-type="table-fn"}   -0.03                                         -0.12                                                     0.06    -0.04 (-0.13 to -0.05) \[[@pone.0168549.ref024]\]   69%
  *Fasting glucose (mmol/L)*   35[^a^](#t004fn002){ref-type="table-fn"}   -0.11[^b^](#t004fn003){ref-type="table-fn"}   -0.19                                                     -0.02   -0.11 (-0.19 to -0.02) \[[@pone.0168549.ref035]\]   57%

Table footnotes:

^**a**^ The China and US sites in Smith (2013) are counted as separate studies.

^**b**^ Significant at the 0.05 level.

Discussion {#sec019}
==========

Summary of evidence {#sec020}
-------------------

Overall, compared to usual care, both pharmacological and behavioural interventions improved fasting glucose levels, but not HbA~1c~ in people with SMI, with behavioural interventions showing a larger difference compared with pharmacological interventions. However, after adjusting for publication bias, there was some evidence that pharmacological interventions may also improve HbA~1c~. Subgroup analyses showed improvements in HbA~1c~ for antipsychotic switching and metformin; and in fasting glucose for metformin. For behavioural interventions, those that included regular physical activity were more effective in lowering fasting glucose than those that did not. Subgroup analysis and meta-regression showed that interventions of longer duration resulted in greater improvements in fasting glucose compared to usual care, and this may help to explain why the small number of studies measuring HbA~1c~ did not show an improvement, as only one of these was greater than 6 months in duration.

Some categories of pharmacological interventions (diabetes and weight loss medications), appeared to have a smaller effect on lowering glycaemic measurements in studies that excluded people with diabetes at baseline compared to the effect observed in studies that did not. However, it was not possible to investigate this robustly because of limited data, and the meta-regression of all pharmacological interventions showed no association between baseline levels of HbA~1c~ or fasting glucose and effect size. For behavioural interventions, studies that included participants with higher baseline glucose levels appeared to be more effective in a meta-regression, although the subgroup analysis showed no difference between studies that excluded those with diabetes compared to those that did not.

Our findings are consistent with previous meta-analyses. Bruins *et al*., \[[@pone.0168549.ref007]\] found a significant improvement in fasting glucose levels with lifestyle interventions (standardised MD = -0.24, 95% CI, \[-0.32, -0.10\]; p = 0.001; n = 8 studies; I^2^ = 0%) but did not include HbA~1c~ in their analysis or explore intervention characteristics. Mizuno *et al*., \[[@pone.0168549.ref006]\] explored pharmacological strategies to counteract the metabolic side effects of antipsychotic medication, and reported statistically significant improvements in fasting glucose for metformin (MD = -0.18mmol/L; 95% CI, \[-0.35, 0.00\]; n = 9 studies; I^2^ = 73%); and in HbA~1c~ for metformin (MD = -0.08%; 95% CI, \[-0.13, -0.03\]; n = 3 studies; I^2^ = 0%) and aripiprazole (MD = -0.65%; 95% CI, \[-1.25, -0.06\]; n = 2 studies; I^2^ = 89%). Our findings were similar but included drugs in addition to aripiprazole in the antipsychotic switching group.

In common with these previous reviews, we found the improvements reported in HbA~1c~ and fasting glucose were modest. However, there was considerable heterogeneity in results. Differences in effect sizes and direction of effect between studies made it difficult to assess the overall effectiveness of interventions. Several studies showed a reduction in fasting glucose and at the same time an increase in HbA~1c~ or vice versa \[[@pone.0168549.ref037]--[@pone.0168549.ref039], [@pone.0168549.ref043], [@pone.0168549.ref054]\]. These results are difficult to explain because logically one would expect a corresponding change, particularly in longer duration studies which would take account of the time required to alter HbA~1c~. However, there are a number of trials that demonstrate that although HbA~1c~ and fasting glucose are well correlated, they do not always respond in similar ways \[[@pone.0168549.ref076]\].

For people with SMI, this relationship may be complicated further by the metabolic side effects of anti-psychotic medication, which will work against interventions designed to improve glycaemic control \[[@pone.0168549.ref077]\]. For example, in several of the pharmacological and behavioural intervention studies, fasting glucose or HbA~1c~ increased in both the intervention and control groups, but with a smaller increase in the intervention group \[[@pone.0168549.ref024], [@pone.0168549.ref031], [@pone.0168549.ref043], [@pone.0168549.ref049], [@pone.0168549.ref056]\]. Through subgroup analysis and meta-regression, we have been able to identify certain intervention and population characteristics that may explain some of the differences in effect between studies, and identify particular interventions that show the most promise. However, these findings should be viewed within the context of methodologically limited trials, and for the antipsychotic switching and behavioural interventions, substantial dropout in follow-up.

Limitations {#sec021}
-----------

Although we included a larger number of studies compared with previous reviews, a limitation of our findings relates to the quantity and quality of evidence included, and the substantial risk of potential bias identified in included studies. We were also unable to fully explore differential effects between those with and without diabetes, or to compare our findings to evidence in the general population because of the lack of data to measure onset of diabetes in those without diabetes, and diabetic complications in those with diabetes. Previous reviews have also commented on the paucity and poor quality of evidence in this area \[[@pone.0168549.ref010], [@pone.0168549.ref014]\]. Strengths of our review include a published protocol, robust search, independent screening and data extraction by at least two reviewers, and the use of appropriate meta-analytic methods to explore the results.

Implications for clinical practice {#sec022}
----------------------------------

These results suggest that antipsychotic switching strategies, metformin, sustained behavioural interventions, and behavioural interventions that include regular physical activity offer the greatest potential to improve glycaemic control in the SMI population. Whilst the effect sizes were modest, such improvements in glycaemic control can help to avoid onset of diabetes and attenuate diabetes complications \[[@pone.0168549.ref011]\], therefore, the small differences reported in key subgroups may still be clinically significant. Also, combining pharmacological and behavioural strategies may incrementally (or perhaps even synergistically) increase effectiveness \[[@pone.0168549.ref034]\]. However, the effect sizes observed were modest when compared to the general population \[[@pone.0168549.ref018], [@pone.0168549.ref078]\], suggesting that tailored interventions which address the specific challenges faced by people with SMI are needed.

In real world settings, the SMI population will face challenges in adhering to new medications or engaging in sustained behavioural interventions involving attendance at regular group sessions \[[@pone.0168549.ref023], [@pone.0168549.ref079]\]. These challenges will likely be compounded when implementing multifaceted interventions. Moreover, we need to reflect carefully before pursuing adjunctive pharmacological therapies in a population for whom polypharmacy is already problematic; and the potential acceptability of switching from an antipsychotic medication providing clinical stability to one which may help to improve physical health, but for which the efficacy in preventing relapse in mental illness is uncertain. These considerations, along with the sparse evidence base, mean that recommendations for clinical practice remain limited. Nonetheless, this review does provide some evidence to support current practice of providing lifestyle interventions and switching to antipsychotics with a better metabolic profile in people with SMI.

Conclusions {#sec023}
===========

Improving diabetes outcomes in SMI is a global priority, but the evidence-base to guide clinical practice is limited. Despite the challenges described above, a number of pharmacological and behavioural approaches warrant further exploration. Metformin is already a well-established treatment in diabetes \[[@pone.0168549.ref017]\]. Its use alongside antipsychotic prescriptions to prevent diabetes merits further investigation. Switching of antipsychotic medication is also common in clinical practice. Research is needed to understand which antipsychotics offer the greatest potential benefit, and to optimise dosage and timing of such interventions in order to reduce glycaemic burden, whilst maintaining clinical stability for people with SMI.

Behavioural interventions show perhaps more promise than pharmacological strategies, but little is known about the behaviour change techniques that might be most effective for people with SMI and diabetes. This is a key area for research, if we are to avoid ever-increasing inequalities in health and access to healthcare, as diabetes management becomes increasingly predicated on self-management. Future research should focus on the design of appropriate interventions, and test the potential acceptability and feasibility of delivering them in a real world setting, before establishing effectiveness in a trial evaluation.
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